The sale enhances Certara's focus on its higher-margin MIDD and clinical intelligence business; monitor updated 2026 guidance post-closing for revised financial outlook and reinvestment plans.
Price Chart
Executive Summary
Certara agreed to sell its regulatory and medical writing business to Veristat for up to $135 million in cash, consisting of $100 million upfront and up to $35 million in earn-outs. The move sharpens focus on its core Model-Informed Drug Development (MIDD) platform and is expected to close in Q2 2026.
Key Financial Metrics
Key Facts
- Certara is selling its regulatory and medical writing business to Veristat
- Total consideration is up to $135 million: $100 million upfront cash and $35 million in contingent earn-outs
- The business generated $50 million in revenue and $17 million in adjusted EBITDA in 2025
- Transaction expected to close in Q2 2026, subject to customary conditions
- Proceeds will be used to accelerate investment in Certara's MIDD platform
Financial Impact
Up to $135 million in proceeds, including $35 million contingent on performance; divests a $50 million revenue business
Risk Factors
- Transaction may not close due to customary closing conditions
- Loss of $50 million in annual revenue and associated EBITDA from the divested business
- Execution risk in redeploying proceeds to drive growth in core platform
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (CERT) — Batch item 1 | 0001104659-26-046358 |
| Document: tm2612400d1_ex99-1.htm | press-3278796 |
| Document: 0001104659-26-046358-index-headers.html | 0001104659-26-046358 |
| Document: 0001104659-26-046358-index.html | 0001104659-26-046358 |
| Document: 0001104659-26-046358.txt | 0001104659-26-046358 |
| PRESS-RELEASE Data (Synthetic) | 0001104659-26-046358 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 16, 2026 6w ago | Institutional Cluster | $8.00 $8.40 | ▲ +5.00% | ▲ +6.98% | $9.36 (+17.00%) |
Aug 4, 2026 8w ago | 8-K | $7.80 $8.10 | ▲ +3.85% | ▲ +5.08% | $9.36 (+20.00%) |
Jul 15, 2026 11w ago | Press Release | $7.28 $8.15 | ▲ +11.95% | ▲ +8.33% | $9.36 (+28.57%) |
Jun 11, 2026 16w ago | Institutional Cluster | $5.27 $6.79 | ▼ −28.84% | ▼ −26.95% | $9.36 (−77.61%) |
May 11, 2026 20w ago | 8-K | $5.13 $5.18 | ▼ −0.97% | ▼ −1.28% | $9.36 (−82.46%) |
May 11, 2026 20w ago | Press Release | $5.13 $5.18 | ▼ −0.97% | ▼ −1.28% | $9.36 (−82.46%) |
Apr 22, 2026 23w ago | 8-K / PRESS-RELEASE | $6.38 $4.59 | ▼ −28.06% | ▼ −31.22% | $9.36 (+46.71%) |
Apr 3, 2026 26w ago | DEFA14A | $5.46 $6.19 | ▲ +13.37% | ▲ +4.39% | $9.36 (+71.43%) |
Mar 30, 2026 26w ago | Court Ruling | $5.68 $6.14 | ▲ +8.10% | ▼ −4.50% | $9.36 (+64.79%) |
Mar 3, 2026 30w ago | Press Release | $7.24 $5.70 | ▼ −21.27% | ▼ −16.87% | $9.36 (+29.28%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access